SOST and plasma cell myeloma: Unlike the DKK1/SOST dual antibody targeting two soluble antagonists, we chose to target both a membrane bound receptor and a soluble Wnt antagonist, DKK1, which is secreted by myeloma cells to suppress bone formation.